Menu

Close

Drug prescription pattern in European neonatal units

Inge Mesek, Georgi Nellis, Jana Lass, Tuuli Metsvaht, Heili Varendi, Helle Visk, Mark A. Turner, Anthony J. Nunn, Jennifer Duncan, Irja Lutsar

Preprint posted on November 05, 2018 https://www.biorxiv.org/content/early/2018/11/05/463240

Baby’s first steps: The association of drug use in European neonatal units with geographic region and gestational age

Selected by Zhang-He Goh

Background of preprint

Drugs are extensively used in neonates to reduce morbidity and mortality, as well as improve their health. However, despite the vulnerable profile of these patients, their drug use not been well studied. The primary difficulty in conducting this research lies in methodological differences across studies done between countries, as the resultant inter-country variation makes the identification of any large-scale trends particularly challenging.

To bridge this research gap, Mesek et al. conducted a sub-study under the auspices of the European Study of Neonatal Exposure to Excipients (ESNEE), a pan-European project. The authors formulated two hypotheses: first, that gestational age (GA) would influence drug use regardless of region, because underlying conditions depend on GA; and second, that drug use should not depend on geographic region, for the same reason.

Therefore, the authors conducted this study, which, like most clinical studies, revolved around a framework containing a trio of core analyses following data collection. First, the baseline characteristics of the sample gathered from the study population were studied to ensure that the analysis would be appropriate, and the descriptive statistics were presented in Table 1 of the study. Then, the data were analysed to test for differences that answered the research question. Finally, interesting or unexpected trends were picked out and the causes underlying these observations were attributed to various factors.

Key findings of preprint

(A) Analysis of participants’ baseline characteristics

In their study, Mesek et al. first presented the baseline characteristics of their sample of the study population in Table 1 of their preprint, which described the distribution of study participants based on geographic region—referring to countries that were broadly classified into East, North, South, and West Europe. A similar analysis was conducted for the distribution of the study population according to the level of maturity as measured by GA—preterm neonates were classified into “extremely preterm”, “very preterm”, “late preterm”, and “term”. The results of this latter analysis were presented in Table 2 of the preprint. Interestingly, differences were observed in the baseline characteristics of the participants across regions and across GA groups in this study. This was itself a subject for further discussion. In a vast majority of clinical studies, we would not expect significant differences to be observed in participants’ baseline characteristics due to their carefully controlled nature.

(B) Comparison of drug use between different GA groups and geographic regions

Mesek et al. were interested in the relationships between three factors: drug use, GA group, and geographic region (Figure 1).

Figure 1. Relationships analysed by Mesek et al. in their preprint.

Comparison of drug use across different GA groups. The authors found a significant downward trend in drug use with increasing GA, with prescription rates among extremely preterms two times higher than term neonates. A few key trends were highlighted:

  1. Caffeine was very commonly used by extremely preterms and very preterms, though this rate decreased steeply for late preterms and term neonates.
  2. Multivitamins were more commonly used among preterms than term neonates.
  3. Vitamin D was used among preterms with similar frequency, but less so among term neonates.
  4. Anti-infectives were used most commonly among extremely preterms.
  5. Extremely preterms were more likely to receive nervous system and cardiovascular drugs than all other groups.
  6. Extremely preterms were more likely to receive drugs for blood and blood-forming organs, as well as for the alimentary system, compared to late preterm and term neonates.
  7. Extremely preterms were more likely to receive anti-infectives compared to late preterms.
  8. Extremely preterms were more likely to receive respiratory system drugs compared to term neonates.

Comparison of drug use across different geographic regions. Mesek et al. highlighted West Europe, which had a significantly higher prescription rate than North, East, and South Europe. The authors then conducted both univariate and multivariate analyses, revealing significant geographic variations in all the most commonly used Anatomical Therapeutic Chemical (ATC) classes, except for cardiovascular drugs. Key trends are summarised in Table 1.

Table 1. Key trends observed in drug use across different geographic regions, compared to East Europe.


Comparison of drug use across different GA groups. Mesek et al. made two key observations. First, the use of anti-infectives was the highest in extremely preterm and term neonates. This was ascribed to separate factors. Extremely preterm neonates tend to have higher rates of infection; while in term neonates, infection is usually the most common cause of hospitalisation. Second, drug use generally declined in patients with older GA; this was attributed to recommendations in guidelines of clinical consensus established by learned societies.

(C) Attribution of interesting or unexpected trends to various causes

Comparison of drug use across different geographic regions. The authors’ findings in this analysis can also be subdivided into two groups: anti-infectives, and other drugs. The prescribing pattern of anti-infectives was attributed to both differences in microbial resistance rates and geographically-differing medical practices. In contrast, the causes of differences observed in the prescribing patterns of other drugs were not as clear. Mesek et al. propose that these were caused by conflicting evidence arising from the dearth of reliable studies and obsolete clinical practice that may not have incorporated the latest results derived from clinical research.

What I like about this preprint

I selected this preprint for two reasons. First, as Mesek et al. point out, it is “the largest multi-country survey of drug use covering neonatal units across Europe and neonates of all GA groups”. Indeed, multicentre collaborations are difficult to conduct, but are tremendously valuable in two ways: they have significant amounts of statistical power, and they also allow for rigorous comparisons between centres in different regions due to the very nature of the study design.

The second reason for choosing this preprint is its significance in the field of clinical research. Due to its power and its multicentre nature, this study provides a compelling basis on which future research can be prioritised. It refines existing research gaps in drug use in neonates into more focussed areas which can be more rigorously studied on a practical level. For example, Mesek et al. note that the use of caffeine in reducing bronchopulmonary dysplasia in preterms with apnea has been met with conflicting evidence. Having identified these smaller, more specific research gaps, future studies can focus on collecting more specific data that would be better able to answer these research questions.

Future directions

Future directions for this work will likely focus on mitigating the limitations highlighted by Mesek et al.:

  • Voluntary participation may have led to data being collected that do not fully represent the countries that participated in this trial. Some countries were also excluded altogether.
  • The definition of late preterms could have influenced results if this population behaved as “very preterms” or as late preterms.
  • Postnatal age could have been a potential confounder.
  • Rarely used drugs may not have been captured representatively due to the nature of the study design.

Therefore, further efforts will focus on changing the study design, collecting more data on variables, and recruiting a greater number of people. To achieve this, more inter-country coordination and collaboration, with major European countries participating in this multicentre effort. Moreover, the methodology used in data collection may also be further standardised to reduce variation introduced from the experimental design.

At the same time, other auxiliary work that would be immensely useful to this study may also be done. These include studies that focus on not just prescribing or drug use patterns, but also healthcare professionals’ opinions on neonatal care. For instance, the frequency with which physicians and pharmacists conform to guidelines published by learned societies could be assessed and reasons for deviations documented to better elucidate the roles of cross-regional cultural factors in influencing healthcare professionals’ clinical decisions. At the same time, in-house guidelines on neonatal care from various healthcare institutions across the four regions could also be juxtaposed to shed further insight on the trends that have been observed in this work. All in all, the baby steps formed by this study point toward further areas for improvement on clinical guidelines for neonates. Hopefully, this will lead healthcare professionals to achieve a standard of therapy that can be customised to each individual patient profile.

Questions for authors

  1. One reason for differences in regional use of anti-infectives is the microbial resistance rate. Is it also possible that the causative microorganisms themselves differ? For example, the antibiotic to be used will often differ depending on whether the causative bacteria are gram-positive or gram-negative. Hence, how much of this variation in the prescribing pattern is likely to be caused by differences in the causative microorganisms themselves, rather than the resistance rates?
  2. How were the geographical regions defined? Which factors decided how the countries were grouped into the respective geographical regions?

Tags: drug use evaluation, neonates

Posted on: 17th November 2018 , updated on: 23rd November 2018

Read preprint (No Ratings Yet)




  • Author's response

    Inge Mesek shared

    Dear Mr Zhang-He,

    On behalf of the co-authors, I would like to thank you for your interest in our study and for highlighting it with a nice overview.

    We are grateful for the opportunity to comment the questions, however, we believe that these two questions have already been covered in our manuscript.

    Have your say

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Sign up to customise the site to your preferences and to receive alerts

    Register here

    Also in the pharmacology and toxicology category:

    Aqueous synthesis of a small-molecule lanthanide chelator amenable to copper-free click chemistry

    Stephanie Cara Bishop, Robert Winefield, Asokan Anbanandam, et al.



    Selected by Zhang-He Goh

    Applications of Machine Learning in Decision Analysis for Dose Management for Dofetilide

    Andrew E Levy, Minakshi Biswas, Rachel Weber, et al.

    AND

    Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer

    Benjamin Schneider, Arnaud Boyer, Joseph Ciccolini, et al.



    Selected by Zhang-He Goh

    Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection

    Rhea Jessica Longley, Michael T White, Eizo Takashima, et al.

    AND

    Antimalarial drug mefloquine kills both trophozoite and cyst stages of Entamoeba

    Conall Sauvey, Gretchen Ehrenkaufer, Anjan Debnath, et al.



    Selected by Zhang-He Goh

    Robust Antibacterial Activity of Tungsten Oxide (WO3-X) Nanodots

    Guangxin Duan, Lu Chen, Zhifeng Jing, et al.



    Selected by Zhang-He Goh

    A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole

    James Andrew Watson, Nathalie Strub-Wourgraft, Antoine Tarral, et al.



    Selected by Zhang-He Goh

    1

    Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity

    S Pieper, Hannah Onafuye, Dennis Mulac, et al.



    Selected by Zhang-He Goh

    Atropselective Oxidation of 2,2',3,3',4,6'-Hexachlorobiphenyl (PCB 132) to Hydroxylated Metabolites by Human Liver Microsomes: Involvement of Arene Oxide Intermediates

    Eric Uwimana, Xueshu Li, Coby Yeung, et al.



    Selected by Zhang-He Goh

    1

    Repurposing the quinoline antibiotic nitroxoline to treat infections caused by the brain-eating amoeba Balamuthia mandrillaris

    Matthew T. Laurie, Corin V. White, Hanna Retallack, et al.



    Selected by Zhang-He Goh
    Close